Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea : A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui)
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Longitudinal analyses are needed to better understand long-term Ebola virus disease (EVD) sequelae. We aimed to estimate the prevalence, incidence, and duration of sequelae and to identify risk factors associated with symptom occurrence among EVD survivors in Guinea.
METHODS: We followed 802 EVD survivors over 48 months and recorded clinical symptoms with their start/end dates. Prevalence, incidence, and duration of sequelae were calculated. Risk factors associated with symptom occurrence were assessed using an extended Cox model for recurrent events.
RESULTS: Overall, the prevalence and incidence of all symptoms decreased significantly over time, but sequelae remained present 48 months after Ebola treatment center discharge with a prevalence of 30.68% (95% confidence interval [CI] 21.40-39.96) for abdominal, 30.55% (95% CI 20.68-40.41) for neurologic, 5.80% (95% CI 1.96-9.65) for musculoskeletal, and 4.24% (95% CI 2.26-6.23) for ocular sequelae. Half of all patients (50.70%; 95% CI 47.26-54.14) complained of general symptoms 2 years' postdischarge and 25.35% (95% CI 23.63-27.07) 4 years' post-discharge. Hemorrhage (hazard ratio [HR], 2.70; P = .007), neurologic (HR 2.63; P = .021), and general symptoms (HR 0.34; P = .003) in the EVD acute phase were significantly associated with the further occurrence of ocular sequelae, whereas hemorrhage (HR 1.91; P = .046) and abdominal (HR 2.21; P = .033) symptoms were significantly associated with musculoskeletal sequelae.
CONCLUSIONS: Our findings provide new insight into the long-term clinical complications of EVD and their significant association with symptoms in the acute phase, thus reinforcing the importance of regular, long-term follow-up for EVD survivors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 12 vom: 16. Dez., Seite 2166-2174 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diallo, Mamadou Saliou Kalifa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cox models |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciab168 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321796640 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321796640 | ||
| 003 | DE-627 | ||
| 005 | 20231225180643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciab168 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321796640 | ||
| 035 | |a (NLM)33621316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diallo, Mamadou Saliou Kalifa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea |b A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Longitudinal analyses are needed to better understand long-term Ebola virus disease (EVD) sequelae. We aimed to estimate the prevalence, incidence, and duration of sequelae and to identify risk factors associated with symptom occurrence among EVD survivors in Guinea | ||
| 520 | |a METHODS: We followed 802 EVD survivors over 48 months and recorded clinical symptoms with their start/end dates. Prevalence, incidence, and duration of sequelae were calculated. Risk factors associated with symptom occurrence were assessed using an extended Cox model for recurrent events | ||
| 520 | |a RESULTS: Overall, the prevalence and incidence of all symptoms decreased significantly over time, but sequelae remained present 48 months after Ebola treatment center discharge with a prevalence of 30.68% (95% confidence interval [CI] 21.40-39.96) for abdominal, 30.55% (95% CI 20.68-40.41) for neurologic, 5.80% (95% CI 1.96-9.65) for musculoskeletal, and 4.24% (95% CI 2.26-6.23) for ocular sequelae. Half of all patients (50.70%; 95% CI 47.26-54.14) complained of general symptoms 2 years' postdischarge and 25.35% (95% CI 23.63-27.07) 4 years' post-discharge. Hemorrhage (hazard ratio [HR], 2.70; P = .007), neurologic (HR 2.63; P = .021), and general symptoms (HR 0.34; P = .003) in the EVD acute phase were significantly associated with the further occurrence of ocular sequelae, whereas hemorrhage (HR 1.91; P = .046) and abdominal (HR 2.21; P = .033) symptoms were significantly associated with musculoskeletal sequelae | ||
| 520 | |a CONCLUSIONS: Our findings provide new insight into the long-term clinical complications of EVD and their significant association with symptoms in the acute phase, thus reinforcing the importance of regular, long-term follow-up for EVD survivors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cox models | |
| 650 | 4 | |a Ebola survivors | |
| 650 | 4 | |a prevalence | |
| 650 | 4 | |a recurrent events | |
| 650 | 4 | |a sequelae | |
| 700 | 1 | |a Toure, Abdoulaye |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Mamadou Saliou |e verfasserin |4 aut | |
| 700 | 1 | |a Kpamou, Cécé |e verfasserin |4 aut | |
| 700 | 1 | |a Keita, Alpha Kabinet |e verfasserin |4 aut | |
| 700 | 1 | |a Taverne, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Msellati, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Thierno Alimou |e verfasserin |4 aut | |
| 700 | 1 | |a Etard, Jean-Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Ecochard, René |e verfasserin |4 aut | |
| 700 | 1 | |a Delaporte, Eric |e verfasserin |4 aut | |
| 700 | 0 | |a PostEboGui Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ayouba, Ahidjo |e investigator |4 oth | |
| 700 | 1 | |a Baize, Sylvain |e investigator |4 oth | |
| 700 | 1 | |a Bangoura, Kaba |e investigator |4 oth | |
| 700 | 1 | |a Barry, Alimou |e investigator |4 oth | |
| 700 | 1 | |a Barry, Moumié |e investigator |4 oth | |
| 700 | 1 | |a Cissé, Mamoudou |e investigator |4 oth | |
| 700 | 1 | |a Cissé, Mohammed |e investigator |4 oth | |
| 700 | 1 | |a Delaporte, Eric |e investigator |4 oth | |
| 700 | 1 | |a Delfraissy, Jean-François |e investigator |4 oth | |
| 700 | 1 | |a Delmas, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Desclaux, Alice |e investigator |4 oth | |
| 700 | 1 | |a Bella Diallo, Saliou |e investigator |4 oth | |
| 700 | 1 | |a Safiatou Diallo, Mamadou |e investigator |4 oth | |
| 700 | 1 | |a Sadjo Diallo, Mariama |e investigator |4 oth | |
| 700 | 1 | |a Étard, Jean-François |e investigator |4 oth | |
| 700 | 1 | |a Etienne, Cécile |e investigator |4 oth | |
| 700 | 1 | |a Faye, Ousmane |e investigator |4 oth | |
| 700 | 1 | |a Fofana, Ibrahima |e investigator |4 oth | |
| 700 | 1 | |a Granouillac, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Izard, Suzanne |e investigator |4 oth | |
| 700 | 1 | |a Kassé, Djenaba |e investigator |4 oth | |
| 700 | 1 | |a Kabinet Keita, Alpha |e investigator |4 oth | |
| 700 | 1 | |a Keita, Sakoba |e investigator |4 oth | |
| 700 | 1 | |a Koivogui, Lamine |e investigator |4 oth | |
| 700 | 1 | |a Kpamou, Cécé |e investigator |4 oth | |
| 700 | 1 | |a Lacarabaratz, Christine |e investigator |4 oth | |
| 700 | 1 | |a Levy Marchal, Claire |e investigator |4 oth | |
| 700 | 1 | |a Levy, Yves |e investigator |4 oth | |
| 700 | 1 | |a Magassouba, N'Fally |e investigator |4 oth | |
| 700 | 1 | |a March, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mendiboure, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Msellati, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Niane, Harissatou |e investigator |4 oth | |
| 700 | 1 | |a Peeters, Martine |e investigator |4 oth | |
| 700 | 1 | |a Pers, Yves-Marie |e investigator |4 oth | |
| 700 | 1 | |a Raoul, Hervé |e investigator |4 oth | |
| 700 | 1 | |a Lamine Sacko, Sidi |e investigator |4 oth | |
| 700 | 1 | |a Savané, Ibrahima |e investigator |4 oth | |
| 700 | 1 | |a Saliou Sow, Mamadou |e investigator |4 oth | |
| 700 | 1 | |a Taverne, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Touré, Abdoulaye |e investigator |4 oth | |
| 700 | 1 | |a Amara Traoré, Fodé |e investigator |4 oth | |
| 700 | 1 | |a Traoré, Falaye |e investigator |4 oth | |
| 700 | 1 | |a Youla, Yamoussa |e investigator |4 oth | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 12 vom: 16. Dez., Seite 2166-2174 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:12 |g day:16 |g month:12 |g pages:2166-2174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab168 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 12 |b 16 |c 12 |h 2166-2174 | ||